177 related articles for article (PubMed ID: 38262706)
1. NKG2A
Qiu Y; Liu L; Jiang W; Xu Z; Wang J; Dai S; Guo J; Xu J
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38262706
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating CD39
Qi Y; Xia Y; Lin Z; Qu Y; Qi Y; Chen Y; Zhou Q; Zeng H; Wang J; Chang Y; Bai Q; Wang Y; Zhu Y; Xu L; Chen L; Kong Y; Zhang W; Dai B; Liu L; Guo J; Xu J
Cancer Immunol Immunother; 2020 Aug; 69(8):1565-1576. PubMed ID: 32306075
[TBL] [Abstract][Full Text] [Related]
4. Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients.
Jiang W; Zeng H; Liu Z; Jin K; Hu B; Chang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
Urol Oncol; 2022 Apr; 40(4):166.e15-166.e25. PubMed ID: 34998671
[TBL] [Abstract][Full Text] [Related]
5. LINC00887 Fosters Development of Clear Cell Renal Cell Carcinoma via Inhibiting CD8+ T Cell Immune Infiltration.
Wu J; Lin R; Zhang L; Wei Y; Zhang R; Cai W; Hu W
Comput Math Methods Med; 2022; 2022():2582474. PubMed ID: 36060659
[TBL] [Abstract][Full Text] [Related]
6. NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
Yan S; Zeng H; Jin K; Shao F; Liu Z; Chang Y; Wang Y; Zhu Y; Wang Z; Xu L; Xu J
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35523436
[TBL] [Abstract][Full Text] [Related]
7. Endosialin-positive tumor-derived pericytes promote tumor progression through impeding the infiltration of CD8
Lu T; Zhang J; Lu S; Yang F; Gan L; Wu X; Song H; Liu S; Xu C; Han D; Yang B; Wen W; Qin W; Yang L
Cancer Immunol Immunother; 2023 Jun; 72(6):1739-1750. PubMed ID: 36646951
[TBL] [Abstract][Full Text] [Related]
8. NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer.
Salomé B; Sfakianos JP; Ranti D; Daza J; Bieber C; Charap A; Hammer C; Banchereau R; Farkas AM; Ruan DF; Izadmehr S; Geanon D; Kelly G; de Real RM; Lee B; Beaumont KG; Shroff S; Wang YA; Wang YC; Thin TH; Garcia-Barros M; Hegewisch-Solloa E; Mace EM; Wang L; O'Donnell T; Chowell D; Fernandez-Rodriguez R; Skobe M; Taylor N; Kim-Schulze S; Sebra RP; Palmer D; Clancy-Thompson E; Hammond S; Kamphorst AO; Malmberg KJ; Marcenaro E; Romero P; Brody R; Viard M; Yuki Y; Martin M; Carrington M; Mehrazin R; Wiklund P; Mellman I; Mariathasan S; Zhu J; Galsky MD; Bhardwaj N; Horowitz A
Cancer Cell; 2022 Sep; 40(9):1027-1043.e9. PubMed ID: 36099881
[TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating TNFRSF9
Li Y; Wang Z; Jiang W; Zeng H; Liu Z; Lin Z; Qu Y; Xiong Y; Wang J; Chang Y; Bai Q; Wang Y; Liu L; Zhu Y; Xu L; Xia Y; Guo J; Xu J
Oncoimmunology; 2020 Oct; 9(1):1838141. PubMed ID: 33178496
[TBL] [Abstract][Full Text] [Related]
10. Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinoma.
Xu Z; Jiang W; Liu L; Qiu Y; Wang J; Dai S; Guo J; Xu J
Cancer Immunol Immunother; 2024 Apr; 73(5):95. PubMed ID: 38607586
[TBL] [Abstract][Full Text] [Related]
11. Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion.
Fu Q; Xu L; Wang Y; Jiang Q; Liu Z; Zhang J; Zhou Q; Zeng H; Tong S; Wang T; Qi Y; Hu B; Fu H; Xie H; Zhou L; Chang Y; Zhu Y; Dai B; Zhang W; Xu J
Eur Urol; 2019 May; 75(5):752-763. PubMed ID: 30293904
[TBL] [Abstract][Full Text] [Related]
12. CD8
Wu X; Jiang D; Liu H; Lu X; Lv D; Liang L
Front Immunol; 2021; 12():745945. PubMed ID: 34970257
[TBL] [Abstract][Full Text] [Related]
13. Tumor infiltrating mast cells determine oncogenic HIF-2α-conferred immune evasion in clear cell renal cell carcinoma.
Xiong Y; Liu L; Xia Y; Qi Y; Chen Y; Chen L; Zhang P; Kong Y; Qu Y; Wang Z; Lin Z; Chen X; Xiang Z; Wang J; Bai Q; Zhang W; Yang Y; Guo J; Xu J
Cancer Immunol Immunother; 2019 May; 68(5):731-741. PubMed ID: 30758643
[TBL] [Abstract][Full Text] [Related]
14. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.
Şenbabaoğlu Y; Gejman RS; Winer AG; Liu M; Van Allen EM; de Velasco G; Miao D; Ostrovnaya I; Drill E; Luna A; Weinhold N; Lee W; Manley BJ; Khalil DN; Kaffenberger SD; Chen Y; Danilova L; Voss MH; Coleman JA; Russo P; Reuter VE; Chan TA; Cheng EH; Scheinberg DA; Li MO; Choueiri TK; Hsieh JJ; Sander C; Hakimi AA
Genome Biol; 2016 Nov; 17(1):231. PubMed ID: 27855702
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a Seven-Gene Signature Associated with CD8
Chen Y; Zhou X; Xie Y; Wu J; Li T; Yu T; Pang Y; Du W
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762031
[TBL] [Abstract][Full Text] [Related]
16. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
[TBL] [Abstract][Full Text] [Related]
17. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of JAK3 promoter methylation and mRNA expression in clear cell renal cell carcinoma.
Long Q; Huang C; Huang J; Meng Q; Cheng Y; Li Y; He L; Chen M; Zhang C; Wang X; Zhu W; Peng J; Shi D; Zheng F; Dong P; Deng W
J Adv Res; 2022 Sep; 40():153-166. PubMed ID: 36100323
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.
Tatli Dogan H; Kiran M; Bilgin B; Kiliçarslan A; Sendur MAN; Yalçin B; Ardiçoglu A; Atmaca AF; Gumuskaya B
Diagn Pathol; 2018 Aug; 13(1):60. PubMed ID: 30144808
[TBL] [Abstract][Full Text] [Related]
20. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
Reustle A; Di Marco M; Meyerhoff C; Nelde A; Walz JS; Winter S; Kandabarau S; Büttner F; Haag M; Backert L; Kowalewski DJ; Rausch S; Hennenlotter J; Stühler V; Scharpf M; Fend F; Stenzl A; Rammensee HG; Bedke J; Stevanović S; Schwab M; Schaeffeler E
Genome Med; 2020 Mar; 12(1):32. PubMed ID: 32228647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
